Revenue from operations surged 30% year-on-year to Rs. 68,645 million
This Orphan Drug Designation from the USFDA underlines the urgent medical need to develop a therapy for sickle cell disease
Glucon-D maintained its leadership position with a 59% MAT market share
Eltrombopag tablets will be produced at the group’s formulation manufacturing facility at SEZ, Ahmedabad
His professional background also includes key experience at Matrix Labs and Sun Pharma
NUFYMCO BLA has been approved by the USFDA
Subscribe To Our Newsletter & Stay Updated